On November 6, BioNTech SE fell 5.06% in Regular Trading, trading at $86.15 per share, with turnover of $58.91 million.

The move followed the company’s latest update that trastuzumab pamirtecan may offer only limited benefit in the HR+/HER2-low breast cancer subgroup, while BioNTech said it is discussing BLA filing plans with DualityBio.

Background context is that the drug’s phase III study had previously met its primary endpoint on progression-free survival, but overall survival data remain immature. The company had also disclosed a small number of severe and fatal adverse events, while interstitial lung disease incidence was higher than in earlier studies, reinforcing investor caution on the drug’s commercialization outlook and the potential breadth of its target population.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)